Cargando…
Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma
We aimed to comprehensively investigate the clinicopathologic and molecular implications of altered epithelial cell adhesion molecule (EPCAM) expression in colorectal carcinoma (CRC). EPCAM immunohistochemical expression, EPCAM 3′ end deletion, EPCAM promoter methylation, microsatellite instability...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Impact Journals LLC
2015
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924648/ https://www.ncbi.nlm.nih.gov/pubmed/26528695 http://dx.doi.org/10.18632/oncotarget.5618 |
_version_ | 1782439893197127680 |
---|---|
author | Kim, Jung Ho Bae, Jeong Mo Song, Young Seok Cho, Nam-Yun Lee, Hye Seung Kang, Gyeong Hoon |
author_facet | Kim, Jung Ho Bae, Jeong Mo Song, Young Seok Cho, Nam-Yun Lee, Hye Seung Kang, Gyeong Hoon |
author_sort | Kim, Jung Ho |
collection | PubMed |
description | We aimed to comprehensively investigate the clinicopathologic and molecular implications of altered epithelial cell adhesion molecule (EPCAM) expression in colorectal carcinoma (CRC). EPCAM immunohistochemical expression, EPCAM 3′ end deletion, EPCAM promoter methylation, microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP) were analyzed in large cohorts of human CRCs. Among 218 MSI-high CRCs, complete loss (CL) of EPCAM expression was observed in two cases, both of which displayed MSH2 deficiency and EPCAM 3′ deletion. Thirty-one of the 218 MSI-high CRCs demonstrated the partial loss (PL) of EPCAM expression without EPCAM deletion or methylation and were correlated with CIMP-high and poor disease-free survival. Histologically, foci exhibiting EPCAM loss in EPCAM-PL tumors were dominantly distributed in poorly differentiated tumor components and/or in the invasive tumor front. The implications of EPCAM-PL were further validated in a consecutive series of 726 CRCs. EPCAM-PL (n = 50; 6.9%) was also associated with CIMP-high and adverse pathologic factors and was confirmed to be an independent poor prognostic factor in CRC (HR, 1.57; 95% CI, 1.04 to 2.39). EPCAM-CL can be used to screen for EPCAM deletion-induced Lynch syndrome-associated CRC, whereas EPCAM-PL can be used as an indicator of tumor aggressiveness and poor prognosis in CRC. |
format | Online Article Text |
id | pubmed-4924648 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2015 |
publisher | Impact Journals LLC |
record_format | MEDLINE/PubMed |
spelling | pubmed-49246482016-07-13 Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma Kim, Jung Ho Bae, Jeong Mo Song, Young Seok Cho, Nam-Yun Lee, Hye Seung Kang, Gyeong Hoon Oncotarget Research Paper: Pathology We aimed to comprehensively investigate the clinicopathologic and molecular implications of altered epithelial cell adhesion molecule (EPCAM) expression in colorectal carcinoma (CRC). EPCAM immunohistochemical expression, EPCAM 3′ end deletion, EPCAM promoter methylation, microsatellite instability (MSI), and the CpG island methylator phenotype (CIMP) were analyzed in large cohorts of human CRCs. Among 218 MSI-high CRCs, complete loss (CL) of EPCAM expression was observed in two cases, both of which displayed MSH2 deficiency and EPCAM 3′ deletion. Thirty-one of the 218 MSI-high CRCs demonstrated the partial loss (PL) of EPCAM expression without EPCAM deletion or methylation and were correlated with CIMP-high and poor disease-free survival. Histologically, foci exhibiting EPCAM loss in EPCAM-PL tumors were dominantly distributed in poorly differentiated tumor components and/or in the invasive tumor front. The implications of EPCAM-PL were further validated in a consecutive series of 726 CRCs. EPCAM-PL (n = 50; 6.9%) was also associated with CIMP-high and adverse pathologic factors and was confirmed to be an independent poor prognostic factor in CRC (HR, 1.57; 95% CI, 1.04 to 2.39). EPCAM-CL can be used to screen for EPCAM deletion-induced Lynch syndrome-associated CRC, whereas EPCAM-PL can be used as an indicator of tumor aggressiveness and poor prognosis in CRC. Impact Journals LLC 2015-10-30 /pmc/articles/PMC4924648/ /pubmed/26528695 http://dx.doi.org/10.18632/oncotarget.5618 Text en Copyright: © 2016 Kim et al. http://creativecommons.org/licenses/by/2.5/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited. |
spellingShingle | Research Paper: Pathology Kim, Jung Ho Bae, Jeong Mo Song, Young Seok Cho, Nam-Yun Lee, Hye Seung Kang, Gyeong Hoon Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma |
title | Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma |
title_full | Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma |
title_fullStr | Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma |
title_full_unstemmed | Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma |
title_short | Clinicopathologic, molecular, and prognostic implications of the loss of EPCAM expression in colorectal carcinoma |
title_sort | clinicopathologic, molecular, and prognostic implications of the loss of epcam expression in colorectal carcinoma |
topic | Research Paper: Pathology |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4924648/ https://www.ncbi.nlm.nih.gov/pubmed/26528695 http://dx.doi.org/10.18632/oncotarget.5618 |
work_keys_str_mv | AT kimjungho clinicopathologicmolecularandprognosticimplicationsofthelossofepcamexpressionincolorectalcarcinoma AT baejeongmo clinicopathologicmolecularandprognosticimplicationsofthelossofepcamexpressionincolorectalcarcinoma AT songyoungseok clinicopathologicmolecularandprognosticimplicationsofthelossofepcamexpressionincolorectalcarcinoma AT chonamyun clinicopathologicmolecularandprognosticimplicationsofthelossofepcamexpressionincolorectalcarcinoma AT leehyeseung clinicopathologicmolecularandprognosticimplicationsofthelossofepcamexpressionincolorectalcarcinoma AT kanggyeonghoon clinicopathologicmolecularandprognosticimplicationsofthelossofepcamexpressionincolorectalcarcinoma |